Kuros Biosciences AG / Key word(s): Study results/Scientific publication Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next  [ … ]

Kuros Biosciences AG / Key word(s): AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.  The Annual Gen [ … ]

Kuros Biosciences AG / Key word(s): Annual Results Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST -    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Bioscienc [ … ]

Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, February 1, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present [ … ]

Kuros Biosciences AG / Key word(s): Regulatory Admission/Market Launch Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand 31.01.2024 / 07:00 CET/CEST MagnetOs™ Granules becomes the third product in the MagnetOs [ … ]

Kuros Biosciences AG / Key word(s): Study results/Preliminary Results Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA 04.01.2024 / 07:00 CET/CEST New level 1 data from the MAXA  [ … ]